Pubblicità
Pubblicità
Feb
27
Scontrino parlante per la detrazione dei medicinali: l’Agenzia delle Entrate semplifica gli adempimenti
Filed Under Il mestiere di farmacista | Leave a Comment
di Giancarlo Nicoli
Federfarma ha diramato la circolare n. 83 che commenta le recenti indicazioni operative impartite dall’Agenzia delle entrate, rispondendo a un’istanza di Federfarma, con la risoluzione n. 10/E del 17 febbraio 2010 in materia di scontrino parlante per la certificazione delle spese sostenute per l’acquisto di medicinali ai fini della relativa detrazione fiscale.
L’Agenzia, in un ottica condivisibile di semplificazione, ha definitivamente chiarito che in caso di pagamento del ticket non è più necessaria la conservazione della ricetta rilasciata dal medico di base, essendo sufficiente lo scontrino recante tale dicitura, poiché riferibile unicamente a farmaci erogati in regime di SSN.
Inoltre è stato precisato che la natura di medicinale dei beni può essere attestata anche mediante abbreviazioni, sigle e/o acronimi e, in caso di acquisto di farmaci senza obbligo di prescrizione medica o da banco, con le indicazioni SOP e OTC.
Fonte: Federfarma
Feb
25
Lettera aperta al signor Sindaco di Bordighera
Filed Under Girare in giro, mangiare, bere, divertirsi | Leave a Comment
di Philip Vardena
Diffondo il testo della lettera, da me inviata in cartaceo al sindaco pro-tempore di Bordighera, arch. Giovanni Bosio, e all’ufficio di corrispondenza di Imperia e Sanremo del quotidiano “Il Secolo XIX” di Genova.
Caro signor Sindaco,
sono stato recentemente in ferie, con la mia famiglia (moglie e due figli, di tre e un anno), nella ridente città da lei amministrata.
Era la prima volta che venivamo, penso di poter dire che altre seguiranno. Abbiamo trovato una accoglienza cordiale da parte del personale dell’albergo e dai negozianti con cui siamo entrati in contatto.
Siamo rimasti favorevolmente colpiti dall’equilibrato sviluppo urbanistico, dalle belle ville e dai giardini. Abbiamo piacevolmente passeggiato in generale un po’ per tutta la città, e in particolare per tutto il lungomare, avanti e indietro, tutti i giorni. Abbiamo notato i lavori per il prolungamento della passeggiata, idea che condividiamo e che abbiamo giudicato positiva per migliorare la vivibilità della città e promuoverne ulteriormente lo sviluppo turistico.
Per i nostri bambini abbiamo apprezzato la presenza di aree recintate dedicate al gioco e la generale tranquillità del luogo.
Tuttavia, c’è una cosa che invece non ho gradito: la presenza di numerosi cani, anche di grossa taglia, senza museruola e qualche volta addirittura senza guinzaglio.
Nei giorni in cui sono rimasto vostro ospite, ho notato il concorso intitolato “Giovani idee per il Futuro di Bordighera“. Cedo gratis, a lei e a chi li vorrà raccogliere, i seguenti miei pensieri.
Perché non istituire una zona della città – penso alla spiaggia e al lungomare – libera da cani? All’inglese, sempre di moda, la si potrebbe chiamare “Dog-free” oppure “Kids-friendly” (beh, per le etichette c’è sempre tempo). In sostanza, una Bordighera ancora più a misura di bambino e di famiglie.
Durante la nostra permanenza, ho notato sul lungomare cani enormi al guinzaglio di padroni del tutto manifestamente incapaci di trattenerli in caso d’imprevisto. Ho assistito a un litigio tra cani – piuttosto inquietante per me, che ero vicino, con due bambini piccoli appresso – tra due minuscoli cagnolini da una parte e due cani (grandi quanto vitelli, e ovviamente senza museruola) trattenuti a stento dai coniugi che li stavano esibendo. Caro signor sindaco, ho visto un padrone portare in spiaggia il proprio cane Dobermann e lasciarlo libero, senza guinzaglio e senza museruola. La pericolosità del gesto è apparsa chiara a tutti coloro che ne sono stati testimoni, tranne evidentemente allo spregiudicato padrone. E non che sia stato l’unico episodio, che ho visto, di cane completamente libero di scorrazzare in spiaggia, tutt’altro.
Di fatto, il cane libero impedisce a tutte le altre persone l’accesso alla spiaggia: cosa che ho vissuto come un sopruso; e mi fa sorgere domande a proposito dell’igiene della spiaggia stessa.
A me sembra che l’attuale situazione di indifferente permissività sia una pericolosa porta aperta, un invito alla disgrazia perché si verifichi.
Non sarebbe meglio prevenire, invece che curare?
Le statistiche sono molto chiare: ogni anno, accusa il Codacons, vengono denunciati 70 mila casi di aggressioni compiute da cani. Il fatto che a provocare la tragedia sia quasi sempre il cane di casa, lo stesso che fino a un istante prima era sempre stato “buonissimo, dolcissimo e affettuosissimo”, è forse l’elemento più inquietante: possiamo passeggiare tranquilli, quando vediamo venirci incontro, liberi come l’aria, questi cani che in un momento d’ira sono capaci di uccidere persino i loro padroni?
La sostanza del mio suggerimento è che l’istituzione di una zona garantita e controllata “senza cani”, che ipotizzerei essere la spiaggia e il lungomare, potrebbe attirare l’interesse dei media, dare pubblicità gratuita alla città, caratterizzare Bordighera come città attenta alle esigenze e alle preoccupazioni del turismo famigliare, incrementare – come conseguenza di tutto quanto esposto sopra – l’economia turistica locale.
La ringrazio per l’attenzione.
Con cordiali saluti,
Giancarlo Nicoli
Comune di Bordighera – il Sindaco
Il Secolo XIX – Uffici di corrispondenza di Imperia e Sanremo
Feb
25
Stereotaxis Reports 16% Revenue Increase in the Fourth Quarter 2009
Filed Under Investimenti, Stereotaxis | Leave a Comment
di Philip Vardena
from the press release
–New Orders Up 22% Sequentially; Second Consecutive Quarterly Increase
–Recurring Revenue Reaches Record $5.1 Million –Cash Burn Declines to $2.9 Million
–Full Year 2009 Revenue Up 27%; Gross Margin Percentage of 67%; Operating Expenses Decrease 14%
ST. LOUIS, Feb 25, 2010 /PRNewswire via COMTEX/ — Stereotaxis, Inc. (Nasdaq: STXS) today reported its financial results for the quarter and the year ended December 31, 2009. Revenue for the recent fourth quarter grew 16% to $14.1 million compared with $12.1 million in the same quarter a year ago. The Company recognized revenue on six Niobe(R) Magnetic Navigation Systems, nine Odyssey(TM) systems and four Odyssey Cinema(TM) systems, totaling $9.0 million. Disposables, services and accessories revenue set another record at $5.1 million, a 51% increase from the fourth quarter of 2008, attributable to favorable pricing and procedure growth. The 2009 fourth quarter operating loss decreased 9% to $5.8 million from $6.4 million in 2008.
For the full year 2009, revenue grew 27% to $51.1 million compared with $40.4 million in 2008. Recurring revenue increased 54% to $18.5 million from $12.0 million in 2008. Gross margin for the year was up 30% to $34.1 million, or 66.7% of sales, compared with 64.9% of sales in 2008. Operating expenses decreased 14%, resulting in a 42% reduction in the operating loss to $23.8 million in 2009 compared with the $41.0 million operating loss in 2008.
Michael P. Kaminski, President and Chief Executive Officer, said, “We are very pleased with our financial performance in 2009. Both systems revenue and revenue from disposables and services grew substantially during the year. During the quarter, we generated new orders totaling $7.7 million, up from $6.3 million in the third quarter and just $5.0 million in the second. The increase in orders is an indication that capital spending by hospitals is improving. The Odyssey platform continues to gain recognition in the market. There was substantial interest in the Odyssey platform at the Atrial Fibrillation Symposium in Boston last month. Physicians recognize Odyssey’s value in integration of diverse sources of diagnostic and other patient information into a single format, which provides improved efficiency, enhanced archiving and a unique opportunity to network labs and sites. We anticipate significant Odyssey revenue in 2010 from non-magnetic labs. We anticipate the economic recovery in the U.S. to result in increased commitments from hospitals for new capital projects. From a financial perspective, we are committed to driving revenue growth, generating solid gross profit margins and controlling our expenses,” Mr. Kaminski concluded.
Fourth Quarter 2009 Financial Performance
Gross margin for the quarter was $9.5 million, or 67.3% of revenue, compared with $8.2 million, or 67.6% of revenue, in the fourth quarter of 2008. Fourth quarter operating expenses increased 5% to $15.3 million from $14.6 million in the fourth quarter of the prior year as 2008 benefited from the reversal of certain non-cash compensation costs related to stock compensation programs. Cash burn improved 36% to $2.9 million for the fourth quarter of 2009 compared with $4.5 million in the fourth quarter of 2008.
The operating loss in the fourth quarter decreased 9% to $(5.8) million compared with $(6.4) million in the prior year. The Company reported a net loss for the fourth quarter of 2009 of $(6.7) million, or $(0.14) per share. This compares with a net loss for the fourth quarter of 2008 of $(7.5) million, or $(0.20) per share. The weighted average shares for the recent fourth quarter totaled 48.4 million compared with 36.7 million in the fourth quarter of last year. The increase was due in large part to the issuance of 7,475,000 shares as part of the secondary stock offering completed in October 2009.
Cash and equivalents at December 31, 2009 totaled $30.5 million, compared with $30.4 million at December 31, 2008. Included in the cash position at the end of 2009 was approximately $27.8 million in net proceeds received from the stock offering during the fourth quarter. Total debt was $23.7 million, including $10 million drawn against the Company’s $30 million line of credit. As previously disclosed, in October 2009 the Company received a commitment to expand its line of credit from $25 million to $30 million and to extend the maturity date from March 31, 2010 to March 31, 2011.
2010 Financial Guidance
The Company provided its outlook for 2010 as follows:
- New capital order growth in excess of 40%
- Total revenue growth in the mid-20% range
- Gross margins above 65%
- Operating expenses between $60 and $65 million
Conference Call Information
The Company has scheduled a conference call for 8:30 a.m. Eastern Time today to discuss its financial results for the fourth quarter. To access the conference call, please dial (877) 941-9205. International participants can call (480) 629-9866. An audio replay of the call will be available for seven days following the call at (800) 406-7325 for U.S. callers or (303) 590-3030 for those calling outside the U.S. The password required to access the replay is 4207018#. The call will also be available on the Internet live and for 90 days thereafter at the following URL:
http://www.videonewswire.com/event.asp?id=66045
About Stereotaxis
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. Stereotaxis’ Odyssey solutions integrate and manage information from disparate information sources, eliminating the challenge of interacting simultaneously with many separate diagnostic systems, driving optimized workflow and improved productivity. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.
(Tables to follow)
STEREOTAXIS, INC. STATEMENTS OF OPERATIONS (1) (Unaudited)
Three Months Ended Twelve Months Ended December 31, December 31, 2009 2008 2009 2008 ---- ---- ---- ---- Revenue System $8,966,960 $8,743,693 $32,661,573 $28,375,880 Disposables, service and accessories 5,114,431 3,382,791 18,487,982 11,989,293 --------- --------- ---------- ---------- Total revenue 14,081,391 12,126,484 51,149,555 40,365,173
Cost of revenue System 3,990,424 3,233,985 13,240,430 12,008,090 Disposables, service and accessories 619,061 693,558 3,781,203 2,169,700 ------- ------- --------- --------- Total cost of revenue 4,609,485 3,927,543 17,021,633 14,177,790
Gross margin 9,471,906 8,198,941 34,127,922 26,187,383
Operating expenses: Research and development 4,012,977 3,561,488 14,260,854 17,422,828 Sales and marketing 7,269,738 5,363,663 28,694,540 28,660,663 General and administration 4,003,449 5,663,051 15,010,490 21,121,164 --------- --------- ---------- ---------- Total operating expenses 15,286,164 14,588,202 57,965,884 67,204,655 ---------- ---------- ---------- ---------- Operating loss (5,814,258) (6,389,261) (23,837,962) (41,017,272) Other income/ (expense) 845,470 - 911,977 - Interest income 10,699 29,205 44,768 194,870 Interest expense (1,752,762) (1,131,965) (4,613,240) (3,063,572) ---------- ---------- ---------- ---------- Net loss $(6,710,851) $(7,492,021) $(27,494,457) $(43,885,974) =========== =========== ============ ============
Net loss per common share: Basic and diluted $(0.14) $(0.20) $(0.63) $(1.20) ====== ====== ====== ======
Weighted average shares used in computing net loss per common share: Basic and diluted 48,374,735 36,714,618 43,344,324 36,585,086 ========== ========== ========== ==========
(1) On September 23, 2009, the Financial Accounting Standards Board ratified Emerging Issues Task Force (EITF) Issue 08-1, creating Accounting Standards Update (ASU) 2009-13 "Multiple-Deliverable Revenue Arrangements". The Company adopted this standard in the fourth quarter of 2009, effective for transactions occurring on or after January 1, 2009. Since there were no material changes to any amounts previously reported in 2009 or 2008, these periods were not required to be restated.
STEREOTAXIS, INC. BALANCE SHEETS
December 31, December 31, 2009 2008 ---- ---- (Unaudited) Assets Current Assets: Cash and cash equivalents $30,546,550 $30,355,657 Accounts receivable, net of allowance of $322,463 and $328,307 in 2009 and 2008, respectively 11,152,648 9,739,008 Current portion of long-term receivables 66,800 197,351 Inventories 4,403,675 8,086,956 Prepaid expenses and other current assets 3,872,535 2,966,510 --------- --------- Total current assets 50,042,208 51,345,482 Property and equipment, net 4,790,310 6,420,600 Intangible assets 1,144,445 1,277,778 Long-term Receivables 138,441 298,123 Other assets 5,112 98,382 ----- ------ Total assets $56,120,516 $59,440,365 =========== ===========
Liabilities and stockholders' equity Current liabilities: Current maturities of long-term debt $3,333,333 $3,901,491 Accounts payable 3,881,205 4,561,928 Accrued liabilities 8,615,287 9,873,818 Deferred contract revenue 7,191,492 9,676,339 Warrants 4,142,614 - --------- --- Total current liabilities 27,163,931 28,013,576
Long term debt, less current maturities 20,346,655 25,271,547 Long term deferred contract revenue 948,574 1,225,656 Other liabilities 20,013 158,905
Stockholders' equity: Preferred stock, par value $0.001; 10,000,000 shares authorized at 2009 and 2008; none outstanding at 2009 and 2008 - - Common stock, par value $0.001; 100,000,000 shares authorized at 2009 and 2008; 50,208,171 and 42,049,792 issued at 2009 and 2008, respectively 50,208 42,050 Additional paid-in capital 331,249,918 300,892,957 Treasury stock, 40,151 shares at 2009 and 2008 (205,999) (205,999) Accumulated deficit (323,452,784) (295,958,327) ------------ ------------ Total stockholders' equity 7,641,343 4,770,681 --------- --------- Total liabilities and stockholders' equity $56,120,516 $59,440,365 =========== ===========
SOURCE: Stereotaxis, Inc.
Pubblicità
Creative Common License
